Literature DB >> 18461292

New aspect of anti-inflammatory action of lipo-prostaglandinE1 in the management of collagen diseases-related skin ulcer.

Hiroyuki Murota1, Yorihisa Kotobuki, Noriko Umegaki, Mamori Tani, Ichiro Katayama.   

Abstract

It is considered that the mechanism in intractable cutaneous ulcer is deeply associated with prolongation at the inflammatory phase. Having evaluated the effects of Lipo-prostaglandin E1 (Lipo-PGE1) with indicators such as the reduction ratio of the ulcer area and the values of the inflammatory markers after dividing them into two groups of collagen diseases and non-collagen diseases and giving them Lipo-PGE1, we managed to obtain the result that Lipo-PGE1 administration could influence various inflammatory markers such as C-reactive protein (CRP), IL-6, and VEGF in addition to reduction of the ulcer region. It also suggested that Lipo-PGE1 has the effect of maintaining an appropriate balance of induction of inflammation and angiogenesis. Additionally, it revealed that Lipo-PGE1 controls the production of cytokines, which are associated with the growth of collagen diseases. From these results, it can be expected that Lipo-PGE1 will act favorably on intractable collagen diseases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18461292     DOI: 10.1007/s00296-008-0589-5

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  22 in total

1.  A form of circulating ICAM-1 in human serum.

Authors:  R Rothlein; E A Mainolfi; M Czajkowski; S D Marlin
Journal:  J Immunol       Date:  1991-12-01       Impact factor: 5.422

2.  Granulocyte/macrophage colony-stimulating factor treatment of human chronic ulcers promotes angiogenesis associated with de novo vascular endothelial growth factor transcription in the ulcer bed.

Authors:  F Cianfarani; R Tommasi; C M Failla; M T Viviano; G Annessi; M Papi; G Zambruno; T Odorisio
Journal:  Br J Dermatol       Date:  2006-01       Impact factor: 9.302

3.  Serum concentrations of vascular endothelial growth factor in collagen diseases.

Authors:  K Kikuchi; M Kubo; T Kadono; N Yazawa; H IHN; K Tamaki
Journal:  Br J Dermatol       Date:  1998-12       Impact factor: 9.302

4.  Role of leukocyte activation in patients with venous stasis ulcers.

Authors:  P J Pappas; S R Fallek; A Garcia; C T Araki; T L Back; W N Durán; R W Hobson
Journal:  J Surg Res       Date:  1995-11       Impact factor: 2.192

5.  Increased levels of circulating intercellular adhesion molecule 1 in the sera of patients with rheumatoid arthritis.

Authors:  J J Cush; R Rothlein; H B Lindsley; E A Mainolfi; P E Lipsky
Journal:  Arthritis Rheum       Date:  1993-08

6.  Soluble intercellular adhesion molecule-1 (sICAM-1) in patients with rheumatoid arthritis and systemic lupus erythematosus.

Authors:  K P Machold; H P Kiener; W Graninger; W B Graninger
Journal:  Clin Immunol Immunopathol       Date:  1993-07

7.  Serum C-reactive protein measurement in pyoderma gangrenosum.

Authors:  I F Rowe; A C Deans
Journal:  Dermatologica       Date:  1986

8.  Increased levels of circulating intercellular adhesion molecule-1 in patients with systemic sclerosis.

Authors:  H Kiener; W Graninger; K Machold; M Aringer; W B Graninger
Journal:  Clin Exp Rheumatol       Date:  1994 Sep-Oct       Impact factor: 4.473

9.  Soluble intercellular adhesion molecule-1 (ICAM-1) antigen in patients with rheumatoid arthritis.

Authors:  S Aoki; K Imai; A Yachi
Journal:  Scand J Immunol       Date:  1993-11       Impact factor: 3.487

10.  Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue.

Authors:  R A Fava; N J Olsen; G Spencer-Green; K T Yeo; T K Yeo; B Berse; R W Jackman; D R Senger; H F Dvorak; L F Brown
Journal:  J Exp Med       Date:  1994-07-01       Impact factor: 14.307

View more
  6 in total

1.  Influence of various treatments including povidone-iodine and healing stimulatory reagents in a rabbit ear wound model.

Authors:  Keitaro Arai; Masashi Yamazaki; Tatsuo Maeda; Takaaki Okura; Ryoji Tsuboi
Journal:  Int Wound J       Date:  2012-07-09       Impact factor: 3.315

2.  Study of molecular mechanism of Prostaglandin E1 in inhibiting coronary heart disease.

Authors:  H J Liu; J W Ma; Z Y Qiao; B Xu
Journal:  Mol Biol Rep       Date:  2013-10-22       Impact factor: 2.316

3.  Effect of Prostaglandin E1 Analog Misoprostol in An Ovalbumin-Induced Allergic Rhinitis Model.

Authors:  Zulkuf Kaya; Muhammed Yayla; Arzu Bilen; Nihal Efe Atilla; Sevilay Ozmen; Irfan Cinar; Zafer Bayraktutan; Vahit Mutlu; Harun Un; Erdem Toktay
Journal:  Eurasian J Med       Date:  2019-02

4.  PGH1, the precursor for the anti-inflammatory prostaglandins of the 1-series, is a potent activator of the pro-inflammatory receptor CRTH2/DP2.

Authors:  Ralf Schröder; Luzheng Xue; Viktoria Konya; Lene Martini; Nora Kampitsch; Jennifer L Whistler; Trond Ulven; Akos Heinemann; Roy Pettipher; Evi Kostenis
Journal:  PLoS One       Date:  2012-03-19       Impact factor: 3.240

5.  An agonist sensitive, quick and simple cell-based signaling assay for determination of ligands mimicking prostaglandin E2 or E1 activity through subtype EP1 receptor: Suitable for high throughput screening.

Authors:  Annirudha J Chillar; Parastoo Karimi; Kathy Tang; Ke-He Ruan
Journal:  BMC Complement Altern Med       Date:  2011-02-07       Impact factor: 3.659

6.  Therapeutic effect of liposomal prostaglandin E1 in acute lower limb ischemia as an adjuvant to hybrid procedures.

Authors:  Jianlin Li; Bing Wang; Yue Wang; Fei Wu; Panfeng Li; Yang Li; Lei Zhao; Wenjun Cui; Yu Ding; Qian An; Jiangtao Si
Journal:  Exp Ther Med       Date:  2013-04-10       Impact factor: 2.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.